Oculis (NASDAQ:OCS) Shares Gap Up – Here’s What Happened

Oculis Holding AG (NASDAQ:OCS) shares gapped up before the market opened on Wednesday . The stock had previously closed at $15.81, but opened at $16.49. Oculis shares last traded at $16.30, with a volume of 2,449 shares.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Oculis in a report on Wednesday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $29.20.

Oculis Price Performance

The firm has a market capitalization of $647.25 million, a P/E ratio of -8.88 and a beta of 0.30. The business’s 50-day simple moving average is $12.73 and its 200 day simple moving average is $12.15. The company has a quick ratio of 5.27, a current ratio of 5.27 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last released its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.13). Oculis had a negative net margin of 7,679.05% and a negative return on equity of 61.33%. The business had revenue of $0.27 million for the quarter, compared to the consensus estimate of $0.28 million. Sell-side analysts forecast that Oculis Holding AG will post -2.19 earnings per share for the current year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.